CVRx (CVRX) Competitors

CVRx (NASDAQ:CVRX) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.

Do institutionals & insiders have more ownership in CVRX or SMTI?

75.3% of CVRx shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 18.9% of CVRx shares are owned by insiders. Comparatively, 54.1% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has preferable valuation and earnings, CVRX or SMTI?

Sanara MedTech has higher revenue and earnings than CVRx. Sanara MedTech is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$39.29M	8.35	-$41.20M	-$2.70	-5.01
Sanara MedTech	$64.99M	5.01	-$4.30M	-$0.99	-37.66

Does the media favor CVRX or SMTI?

In the previous week, Sanara MedTech had 2 more articles in the media than CVRx. MarketBeat recorded 4 mentions for Sanara MedTech and 2 mentions for CVRx. Sanara MedTech's average media sentiment score of 0.98 beat CVRx's score of 0.51 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CVRx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor CVRX or SMTI?

CVRx received 9 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 69.23% of users gave CVRx an outperform vote while only 54.55% of users gave Sanara MedTech an outperform vote.

Company	Underperform	Outperform
CVRx	Outperform Votes 27 69.23%	Underperform Votes 12 30.77%
Sanara MedTech	Outperform Votes 18 54.55%	Underperform Votes 15 45.45%

Which has more volatility and risk, CVRX or SMTI?

CVRx has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Do analysts recommend CVRX or SMTI?

CVRx presently has a consensus target price of $15.83, suggesting a potential upside of 17.11%. Sanara MedTech has a consensus target price of $44.00, suggesting a potential upside of 18.03%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts plainly believe Sanara MedTech is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sanara MedTech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is CVRX or SMTI more profitable?

Sanara MedTech has a net margin of -10.71% compared to CVRx's net margin of -123.75%. Sanara MedTech's return on equity of -19.86% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-123.75%	-89.06%	-52.56%
Sanara MedTech	-10.71%	-19.86%	-10.91%

Summary

Sanara MedTech beats CVRx on 12 of the 18 factors compared between the two stocks.